Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of etirinotecan pegol [NKTR 102] in patients with refractory solid tumours

Next Previous
Trial Profile

Phase I study of etirinotecan pegol [NKTR 102] in patients with refractory solid tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Gastrointestinal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nektar Therapeutics

    • Most Recent Events

    • 24 Oct 2008 Positive interim results were presented at the 20th EORTC -NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics', according to a Nektar media release.
    • 24 Oct 2008 In a media release, Nektar announced that the company expects to present complete results at additional scientific forums later this year.
    • 02 Jun 2008 Results have been presented at ASCO 2008; complete results are expected later in 2008, according to a Nektar Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top